Pharmacotherapy for Status Epilepticus

Drugs

Volumn 75, Issue 13, 2015, Pages 1499-1521

  Trinka, Eugen ^a,c,d   Höfler, Julia ^a,c   Leitinger, Markus ^a,c   Brigo, Francesco ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF SALZBURG   (Austria)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOMETHIAZOLE; CLONAZEPAM; CORTICOSTEROID; DIAZEPAM; ETIRACETAM; ETOMIDATE; FOSPHENYTOIN SODIUM; HARKOSERIDE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; ISOFLURANE; KETAMINE; LIDOCAINE; LORAZEPAM; MAGNESIUM; MIDAZOLAM; PARALDEHYDE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; THIOPENTAL; TOPIRAMATE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE BRAIN DISEASE; AGITATION; ANGIONEUROTIC EDEMA; ARTIFICIAL VENTILATION; ATAXIA; ATRIOVENTRICULAR BLOCK; CASE STUDY; CEREBELLUM ATROPHY; COMPARTMENT SYNDROME; CONTINUOUS INFUSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; EPILEPTIC STATE; EXTRAVASATION; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPERAMMONEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; IMMUNOTHERAPY; INCIDENCE; INFECTION; MEDLINE; METABOLIC ACIDOSIS; MORBIDITY; MORTALITY; PARALYTIC ILEUS; PAROXYSMAL ASYSTOLE; PLASMAPHERESIS; PRURITUS; PURPLE GLOVE SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY STATUS EPILEPTICUS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUPER REFRACTORY STATUS EPILEPTICUS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TISSUE NECROSIS; WITHDRAWAL SYNDROME; PATHOPHYSIOLOGY; STATUS EPILEPTICUS;

ANESTHETICS; ANTICONVULSANTS; BENZODIAZEPINES; HUMANS; STATUS EPILEPTICUS;

EID: 84941173925     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0454-2     Document Type: Review

References (221)

1. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-2.
2. Bauer G, Trinka E. Nonconvulsive status epilepticus and coma. Epilepsia. 2010;51(2):177-90.
3. Drislane FW. Presentation, evaluation, and treatment of nonconvulsive status epilepticus. Epilepsy Behav. 2000;1(5):301-14.
4. Trinka E, Hesdorffer D, Rossetti AO, Scheffer I, Shinnar S, Shorvon S, Lowenstein D. A definition and classification of status epilepticus - report of the task force on classification of status epilepticus. Epilepsia. 2015. doi: 10.1111/epi.13121.
5. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia. 2001;42(8):1031-5.
6. Logroscino G, Hesdorffer DC, Cascino G, Hauser WA, Coeytaux A, Galobardes B, Morabia A, Jallon P. Mortality after a first episode of status epilepticus in the united states and europe. Epilepsia. 2005;46(Suppl 11):46-8.
7. Logroscino G, Hesdorffer DC, Cascino GD, Annegers JF, Bagiella E, Hauser WA. Long-term mortality after a first episode of status epilepticus. Neurology. 2002;58(4):537-41.
8. Sokic DV, Jankovic SM, Vojvodic NM, Ristic AJ. Etiology of a short-term mortality in the group of 750 patients with 920 episodes of status epilepticus within a period of 10 years (1988-1997). Seizure. 2009;18(3):215-9.
9. Sutter R, Marsch S, Fuhr P, Ruegg S. Mortality and recovery from refractory status epilepticus in the intensive care unit: A 7-year observational study. Epilepsia. 2013;54(3):502-11.
10. Leitinger M, Holler Y, Kalss G, Rohracher A, Novak HF, Hofler J, Dobesberger J, Kuchukhidze G, Trinka E. Epidemiology-based mortality score in status epilepticus (emse). Neurocrit care. 2015;22(2):273-82.
11. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12(4):316-25.
12. Waterhouse EJ, DeLorenzo RJ. Status epilepticus in older patients: Epidemiology and treatment options. Drugs Aging. 2001;18(2):133-42.
13. Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, Katsarou N, Hamer HM. Incidence of status epilepticus in adults in germany: a prospective, population-based study. Epilepsia. 2001;42(6):714-8.
14. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in rochester, minnesota, 1965-1984. Neurology. 1998;50(3):735-41.
15. Vignatelli L, Rinaldi R, Galeotti M, de Carolis P, D'Alessandro R. Epidemiology of status epilepticus in a rural area of northern italy: A 2-year population-based study. Eur J Neurol. 2005;12(11):897-902.
16. Vignatelli L, Tonon C, D'Alessandro R. Bologna Group for the Study of Status E: Incidence and short-term prognosis of status epilepticus in adults in bologna, italy. Epilepsia. 2003;44(7):964-8.
17. Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol. 2004;11(12):800-10.
18. Neville BG, Chin RF, Scott RC. Childhood convulsive status epilepticus: epidemiology, management and outcome. Acta Neurol Scand. 2007;115(4):21-4.
19. DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia. 1992;33(Suppl 4):S15-25.
20. Litt B, Wityk RJ, Hertz SH, Mullen PD, Weiss H, Ryan DD, Henry TR. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia. 1998;39(11):1194-202.
21. Sung CY, Chu NS. Status epilepticus in the elderly: etiology, seizure type and outcome. Acta Neurologica Scandinavica. 1989;80:51-6.
22. Towne AR. Epidemiology and outcomes of status epilepticus in the elderly. Int Rev Neurobiol. 2007;81:111-27.
23. Shorvon SD, Trinka E, Walker MC. The proceedings of the first London colloquium on status epilepticus - University College London, April 12-15, 2007. Introduction. Epilepsia. 2007;48(Suppl 8):1-3.
24. Wolf P, Trinka E, Bauer G. Absence status epilepticus: The first documented case? Epilepsia. 2007;48(Suppl. 8):4-5.
25. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [part1]. Am J Insanity. 1903;60:291-306.
26. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [an artical in 3 parts.]. Am J Insanity. 1903;60:291-306, 260, 645-675, 261, 281-108.
27. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [part 3]. Am J Insanity. 1904;61:81-108.
28. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-18.
29. Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A "malignant" variant of status epilepticus. Arch Neurol. 2005;62(9):1428-31.
30. Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in europe: Consensus document from a workshop at the first london colloquium on status epilepticus. Epilepsia. 2008;49(7):1277-85.
31. Jones S, Pahl C, Trinka E, Nashef L. A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Pract Neurol. 2014;14(3):194-7.
32. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, Holtkamp M. European Federation of Neurological S: Efns guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348-55.
33. Janz D. Historical vignette: medical treatment of status epilepticus. Epilepsia. 2013;54(Suppl 6):3-10.
34. Neligan A, Shorvon SD. The history of status epilepticus and its treatment. Epilepsia. 2009;50(Suppl 3):56-68.
35. Prasad K, Al Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2005;4:CD003723.
36. Prasad K, Krishnan PR, Al Roomi K, Sequeira R. Anticonvulsant therapy for status epilepticus. Br J Clin Pharmacol. 2007;63(6):640-7.
37. Brigo F, Storti M, Del Felice A, Fiaschi A, Bongiovanni LG. Iv valproate in generalized convulsive status epilepticus: A systematic review. Eur J Neurol. 2012;19(9):1180-91.
38. Haynes RB. Of studies, syntheses, synopses, summaries, and systems: the "5s" evolution of information services for evidence-based healthcare decisions. Evid Based Med. 2006;11(6):162-4.
39. Trinka E. Benzodiazepines used primarily for emergency treatment (diazepam, lorazepam, and midazolam). In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsies. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 470-84.
40. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O'Neil N, Neuhaus JM, Segal MR, Lowenstein DH. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631-7.
41. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. J Am Med Assoc. 1983;249:1452-4.
42. Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37(8):682-8.
43. Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, Gonzalez V, Lichenstein R, Stanley R, Brousseau DC, Grubenhoff J, et al. Lorazepam vs diazepam for pediatric status epilepticus: A randomized clinical trial. JAMA. 2014;311(16):1652-60.
44. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W, Investigators N. Intramuscular versus intravenous therapy for prehospital status epilepticus. The New England journal of medicine. 2012;366(7):591-600.
45. Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;9:CD003723.
46. Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol. 2001;41(11):1225-31.
47. Anderson M, Tambe P, Sammons H, Mulla H, Cole R, Choonara I. Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur J Clin Pharmacol. 2012;68(2):155-9.
48. Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: A randomized open-label study. Epilepsia. 2011;52(4):788-93.
49. Cereghino JJ, Cloyd JC, Kuzniecky RI. Rectal diazepam gel for treatment of acute repetitive seizures in adults. Arch Neurol. 2002;59(12):1915-20.
50. Cereghino JJ, Mitchell WG, Murphy J, Kriel RL, Rosenfeld WE, Trevathan E. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The north american diastat study group. Neurology. 1998;51(5):1274-82.
51. Kriel RL, Cloyd JC, Pellock JM, Mitchell WG, Cereghino JJ, Rosman NP. Rectal diazepam gel for treatment of acute repetitive seizures. The north american diastat study group. Pediatr Neurol. 1999;20(4):282-8.
52. Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, Matsuo F, Sharp GB, Conry JA, Bergen DC, Bell WE. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338(26):1869-75.
53. Remy C, Jourdil N, Villemain D, Favel P, Genton P. Intrarectal diazepam in epileptic adults. Epilepsia. 1992;33(2):353-8.
54. Congdon PJ, Forysthe WI. Intravenous clonazepam in the treatment of status epilepticus in children. Epilepsia. 1980;21:97-102.
55. Singh AN, Le Morvan P. Treatment of status epilepticus with intravenous clonazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6):539-42.
56. Navarro V, Dagron C, Demeret S, An K, Lamhaut L, Bolgert F, Baulac M, Carli P. A prehospital randomized trial in convulsive status epilepticus. Epilepsia. 2011;52(Suppl 8):48-9.
57. Patsalos PN, Bell DM, Richards G, Sander JWAS, Oxley JR, Dhillion S, Cromarty J. Pharmacokinetic evaluation of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsia. 1991;32(suppl. 1):29.
58. Gathwala G, Goel M, Singh J, Mittal K. Intravenous diazepam, midazolam and lorazepam in acute seizure control. Indian J Pediatr. 2012;79(3):327-32.
59. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83-6.
60. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253-5.
61. Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures. J Neurol. 2013;260(2):470-4.
62. Fisgin T, Gurer Y, Tezic T, Senbil N, Zorlu P, Okuyaz C, Akgun D. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: Prospective randomized study. J Child Neurol. 2002;17(2):123-6.
63. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, Martland T, Berry K, Collier J, Smith S, Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205-10.
64. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009;31(10):744-9.
65. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623-6.
66. Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58-64.
67. Shah I, Deshmukh CT. Intramuscular midazolam vs intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72(8):667-70.
68. Carter C. Use of parenteral diphenylhydantoin (dilantin) sodium in control of status epilepticus. Arch Neurol Psychiatry. 1958;79:136-7.
69. Wilder BJ, Ramsay RE, Willmore LJ, Feussner GF, Perchalski RJ, Shumate JB. Efficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics of central nervous system penetration. Ann Neurol. 1977:1;511-8.
70. Feddersen B, Trinka E. Status epilepticus. Nervenarzt. 2012;83(2):187-94.
71. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin in acute treatment of seizures. Neurology. 1979;29(11):1474-9.
72. Leppik IE, Patrick BK, Cranford RE. Treatment of acute seizures and status epilepticus with intravenous phenytoin. In: Escueta AVD, Wasterlain CG, Treiman DM, Porter RJ, editors. Status epileptics: mechaisms of brain damage and treatment. Advances in neurology, vol. 34. New York: Raven Press; 1983. pp. 447-52.
73. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42(9):1156-9.
74. O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51(4):1034-9.
75. Appleton RE, Gill A. Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure. 2003;12(6):369-72.
76. Chhabra P, Gupta N, Kaushik A. Compartment syndrome as a spectrum of purple glove syndrome following intravenous phenytoin administration in a young male: A case report and review of literature. Neurology India. 2013;61(4):419-20.
77. McWilliam PKA. Intravenous phenytoin sodium in continuous convulsions in children. Lancet. 1958;2:1147-1149.
78. Leppik IE, Patrick BK, Cranford RE. Treatment of acute seizures and status epilepticus with intravenous phenytoin. Adv Neurol. 1983;34:447-51.
79. Wallis W, Kutt H, McDowell F. Intravenous diphenyl hydantoin treatment of acute repetitive seizures. Neurology. 1968;18:513-25.
80. von Albeert HH. A new phenytoin infusion concentrate for status epilepticus. In: Escueta AVD, Wasterlain CG, Treiman DM, Porter RJ, editors. Status epilepticus: mechanisms of brain damage and treatment. Advances in neruology, vol. 34. New York: Raven Press; 1983. pp. 453-456.
81. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med. 1998;339(12):792-8.
82. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: A pilot study. Neurology. 2006;67(2):340-2.
83. Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527-32.
84. Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, Lampl Y. Treatment of status epilepticus and acute repetitive seizures with i.V. Valproic acid vs phenytoin. Acta Neurol Scand. 2008;118(5):296-300.
85. Trinka E. What is the relative value of the standard anticonvulsants: phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam? Epilepsia. 2009;50(Suppl 12):40-3.
86. Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, Barkley GL, Leppik IE, Knapp LE. Intramuscular fosphenytoin (cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res. 1997;28(3):181-7.
87. Wilder BJ, Campbell K, Ramsay RE, Garnett WR, Pellock JM, Henkin SA, Kugler AR. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol. 1996;53(8):764-8.
88. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970-6.
89. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695-714.
90. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223-44.
91. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf. 2006;29(1):1-21.
92. Gerstner T, Busing D, Bell N, Longin E, Kasper JM, Klostermann W, Hebing B, Hanefeld F, Eckel U, Hoffmann R, Bettendorf U, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol. 2007;42(1):39-48.
93. Konig SA, Schenk M, Sick C, Holm E, Heubner C, Weiss A, Konig I, Hehlmann R. Fatal liver failure associated with valproate therapy in a patient with friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia. 1999;40(7):1036-40.
94. Konig SA, Siemes H, Blaker F, Boenigk E, Gross-Selbeck G, Hanefeld F, Haas N, Kohler B, Koelfen W, Korinthenberg R. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia. 1994;35(5):1005-15.
95. Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr J Med Sci. 1984;20(1):46-9.
96. Hussein Z, Mukherjee D, Lamm J, Cavanaugh JH, Granneman GR. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol. 1994;34(7):754-9.
97. Hussein Z, Patterson KJ, Lamm JE, Cavanaugh JH, Granneman GR. Effect of infusion duration on valproate pharmacokinetics. Biopharm Drug Dispos. 1993;14(5):389-99.
98. Honack D, Loscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 1992;13(3):215-21.
99. Walton NY, Treiman DM. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 1992;12(3):199-205.
100. Trinka E, Hofler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS drugs. 2014;28(7):623-39.
101. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia. 2000;41(10):1342-5.
102. Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia. 2007;48(3):478-83.
103. Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid iv administration of valproic acid for status epilepticus. Neurology. 2005;64(2):353-5.
104. Kramer G, Bergmann A, Deshpande LS, Kînig S, Kurth C, Kurlemann G, Loscher W, Luef G, Meierkord H, Noachtar S, Pohlmann-Eden B, et al. Current place of intravenous valproic acid in the treatment of generalized tonic-clonic status epilepticus. Aktuelle Neurol. 2005;32(5):263-74.
105. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55(5):722-4.
106. Embacher N, Karner E, Wanschitz J, Beer R, Trinka E. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13(10):e5-6.
107. Trinka E, Dobesberger J, Brîssner G, Walser G, Embacher N, Unterberger I, Pittschieler S, Luef G, Haberlandt E, Auckenthaler A, Schmutzhard E, et al. Treatment of status epilepticus. A retrospective analysis of 248 patients. Epilepsia. 2006;47(s3):16.
108. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials. Epilepsy Res. 2005;64(1-2):1-11.
109. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol. 2005;28(2):72-8.
110. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-24.
111. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58(2-3):167-74.
112. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl 8):35-8.
113. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on levetiracetam. Ther Adv Neurol Dis. 2009;2(2):79-91.
114. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21(4):233-6.
115. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23(3):167-74.
116. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645-8.
117. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology. 1988;38:202-7.
118. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59(2):205-10.
119. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76(4):534-9.
120. Kalviainen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: A guide to treatment. CNS Drugs. 2005;19(9):759-68.
121. Rossetti AO. Which anesthetic should be used in the treatment of refractory status epilepticus? Epilepsia. 2007;48(Suppl 8):52-5.
122. Holtkamp M. The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol. 2007;20(2):188-93.
123. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146-53.
124. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-28.
125. Niermeijer JM, Uiterwaal CS, Van Donselaar CA. Propofol in status epilepticus: Little evidence, many dangers? J Neurol. 2003;250(10):1237-40.
126. Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656-64.
127. Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106-10.
128. Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, Hirsch LJ, Mayer SA, Claassen J. High-dose midazolam infusion for refractory status epilepticus. Neurology. 2014;82(4):359-65.
129. Zhan RZ, Qi S, Wu C, Fujihara H, Taga K, Shimoji K. Intravenous anesthetics differentially reduce neurotransmission damage caused by oxygen-glucose deprivation in rat hippocampal slices in correlation with n-methyl-d-aspartate receptor inhibition. Crit Care Med. 2001;29(4):808-13.
130. Marik PE. Propofol: therapeutic indications and side-effects. Current Pharm Des. 2004;10(29):3639-49.
131. Marik PE. Propofol: an immunomodulating agent. Pharmacotherapy. 2005;25(5 Pt 2):28S-33S.
132. Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia. 2007;48(5):1002-6.
133. Mayette M, Gonda J, Hsu JL, Mihm FG. Propofol infusion syndrome resuscitation with extracorporeal life support: a case report and review of the literature. Ann Intensiv Care. 2013;3(1):32.
134. Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract. 2015. doi: 10.1155/2015/260385.
135. Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4-10.
136. Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2012;8:CD009202.
137. Lowenstein DH, Aminoff MJ, Simon RP. Barbiturate anesthesia in the treatment of status epilepticus. Clinical experience of 14 patients. Neurology. 1988;38:395-400.
138. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: Mediating mechanisms and prophylactic measures. Anesth Analg. 2003;97(5):1331-9.
139. Stover JF, Stocker R. Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury. Eur J Clin Pharmacol. 1998;54(7):529-34.
140. Tian J, Chau C, Hales TG, Kaufman DL. Gaba(a) receptors mediate inhibition of t cell responses. J Neuroimmunol. 1999;96(1):21-8.
141. Kofke WA, Young RSK, Davis P, Woelfel SK, Gray L, Johnson D, Gelb A, Meeke R, Warner DS, Pearson KS, Gibson JR et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology. 1989;71:653-9.
142. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol. 2004;61(8):1254-9.
143. Rossetti AO. Novel anesthetics and other treatment strategies for refractory status epilepticus. Epilepsia. 2009;50(Suppl 12):51-3.
144. van den Heuvel I, Wurmb TE, Bottiger BW, Bernhard M. Pros and cons of etomidate - more discussion than evidence? Curr Opin Anaesthesiol. 2013;26(4):404-8.
145. Yeoman P, Hutchinson A, Byrne A, Smith J, Durham S. Etomidate infusions for the control of refractory status epilepticus. Intensiv Care Med. 1989;15:255-9.
146. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42(2-3):117-22.
147. Kapur J, Coulter DA. Experimental status epilepticus alters gamma-aminobutyric acid type a receptor function in ca1 pyramidal neurons. Ann Neurol. 1995;38(6):893-900.
148. Mazarati AM, Wasterlain CG. N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;265(3):187-90.
149. Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105(1-2):183-8.
150. Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, Al-Otaibi A, Kilbride R, Fernandez IS, Mendoza L, Samuel S, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498-503.
151. Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol. 2010;33(3):165-7.
152. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9(3):269-72.
153. Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care. 2012;16(2):299-305.
154. Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82(2-3):219-22.
155. Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care. 2006;4(1):35-46.
156. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51(6):1765-6.
157. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4(1):70-5.
158. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20(9):723-6.
159. Zeiler FA, Kaufmann AM, Gillman LM, West M, Silvaggio J. Ketamine for medically refractory status epilepticus after elective aneurysm clipping. Neurocrit Care. 2013;19(1):119-24.
160. Walker MC, Howard RS, Smith SJ, Miller DH, Shorvon SD, Hirsch NP. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM. 1996;89(12):913-20.
161. Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2010;10:CD000128.
162. Storchheim F. Status epilepticus treated by magnesium sulphate, injected intravenously. J Am Med Assoc. 1933;101:1313-4.
163. Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM. Magnesium treatment for patients with refractory status epilepticus due to polg1-mutations. J Neurol. 2011;258(2):218-22.
164. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3-9.
165. Hottinger A, Sutter R, Marsch S, Ruegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS drugs. 2012;26(9):761-72.
166. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr. 2014;14(1 Suppl):3-7.
167. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11-21.
168. Vezzani A, Balosso S, Aronica E, Ravizza T. Basic mechanisms of status epilepticus due to infection and inflammation. Epilepsia. 2009;50(Suppl 12):56-7.
169. Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojarvi J, Doty P. Examining the clinical utility of lacosamide: pooled analyses of three phase ii/iii clinical trials. CNS Drugs. 2010;24(12):1041-54.
170. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308-17.
171. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today. 2008;44(1):35-40.
172. Krauss G, Ben-Menachem E, Mameniskiene R, Vaiciene-Magistris N, Brock M, Whitesides JG, Johnson ME, Group SPS. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia. 2010;51(6):951-7.
173. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008;49(3):418-24.
174. Wasterlain CG, Stohr T, Matagne A. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res. 2011;94(1-2):10-7.
175. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009;14(2):429-31.
176. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393-404.
177. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, Tilz C, Trinka E. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137-41.
178. Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148-52.
179. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clinical Risk Manag. 2009;5:757-66.
180. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20(4):725-7.
181. Kubova H, Rejchrtova J, Redkozubova O, Mares P. Outcome of status epilepticus in immature rats varies according to the paraldehyde treatment. Epilepsia. 2005;46(Suppl 5)38-42.
182. Rowland AG, Gill AM, Stewart AB, Appleton RE, Al Kharusi A, Cramp C, Yeung LK. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. Arch Dis Child. 2009;94(9):720-3.
183. Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: An open randomised trial. Lancet. 2006;367(9522):1591-7.
184. Bernhard CG, Bohm E, Hojeberg S. A new treatment of status epilepticus; intravenous injections of a local anesthetic (lidocaine). AMA Archiv Neurol Psychiatry. 1955;74(2):208-14.
185. Hattori H, Yamano T, Hayashi K, Osawa M, Kondo K, Aihara M, Haginoya K, Hamano S, Izumi T, Kaneko K, Kato I, et al. Effectiveness of lidocaine infusion for status epilepticus in childhood: a retrospective multi-institutional study in japan. Brain Dev. 2008;30(8):504-12.
186. Kobayashi O, Iwasaki Y, Yamanouchi H, Sugai K. A case of refractory status epilepticus associated with aberrant intracranial shunt tube: efficacy of lidocaine in the determination of the epileptic focus. No To Hattatsu. 1994;26(4):329-34.
187. Yildiz B, Citak A, Ucsel R, Karabocuoglu M, Aydinli N, Uzel N. Lidocaine treatment in pediatric convulsive status epilepticus. Pediatr Int. 2008;50(1):35-9.
188. Walker IA, Slovis CM. Lidocaine in the treatment of status epilepticus. Acad Emerg Med. 1997;4(9):918-22.
189. Hamano S, Sugiyama N, Yamashita S, Tanaka M, Hayakawa M, Minamitani M, Yoshinari S, Eto Y. Intravenous lidocaine for status epilepticus during childhood. Dev Med Child Neurol. 2006;48(3):220-2.
190. Sugiyama N, Hamano S, Mochizuki M, Tanaka M, Eto Y. Efficacy of lidocaine on seizures by intravenous and intravenous-drip infusion. No To Hattatsu. 2004;36(6):451-4.
191. Garcia Garcia MJ, Lopez-Herce Cid J, Martinez Bermejo A, Perdikidi Olivieri L, Rubio de la Iglesia F, Hernandez Gonzalez J. Teatment of refractory status convulsivus with chlormethiazole. An Esp Pediatr. 1988;29(4):324-6.
192. Harvey PK, Higenbottam TW, Loh L. Chlormethiazole in treatment of status epilepticus. Br Med J. 1975;2(5971):603-5.
193. Martinovic Z, Jovic N. Chlormethiazole in the treatment of complex partial epileptic status in childhood. Srp Arh Celok Lek. 1991;119(1-2):53-7.
194. Miller P, Kovar I. Chlormethiazole in the treatment of neonatal status epilepticus. Postgrad Med J. 1983;59(698):801-2.
195. Miller P, Kovar I. Chlormethiazole in the treatment of neonatal status epilepticus. Postgrad Med J. 1983;59:801-2.
196. Loscher W, Honack D. Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Epilepsia. 1997;38(1):106-13.
197. Loscher W, Honack D, Richter A, Schulz HU, Schurer M, Dusing R, Brewster ME. New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia. 1995;36(3):255-61.
198. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. Preliminary study on the development of nanoemulsions for carbamazepine intravenous delivery: an investigation of drug polymorphic transition. Drug Dev Ind Pharm. 2008;34(1):53-8.
199. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process. Int J Pharm. 2007;342(1-2):231-9.
200. Ahmed GF, Brundage RC, Marino SE, Cloyd JC, Leppik IE, Pennell PB, Ramsay RE, Birnbaum AK. Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol. 2013;53(3):276-84.
201. Franco V, Iudice A, Grillo E, Citraro R, De Sarro G, Russo E. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. Exp Opin Pharmacother. 2014;15(5):637-44.
202. Patel V, Cordato DJ, Malkan A, Beran RG. Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus. Epilepsy Behav. 2014;31:31-33.
203. Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66(11):1736-8.
204. Rossetti AO, Novy J, Ruffieux C, Olivier P, Foletti GB, Hayoz D, Burnand B, Logroscino G. Management and prognosis of status epilepticus according to hospital setting: a prospective study. Swiss Med Wkly. 2009;139(49-50):719-23.
205. Sutter R, Kaplan PW, Marsch S, Hammel EM, Ruegg S, Ziai WC. Early predictors of refractory status epilepticus: an international two-center study. Eur J Neurol. 2015;22(1):79-85.
206. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27-34.
207. Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260(2):421-8.
208. Aranda A, Foucart G, Ducasse JL, Grolleau S, McGonigal A, Valton L. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia. 2010;51(10):2159-67.
209. Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: Pathophysiology and treatment. Pharm World Sci. 1993;15(1):17-28.
210. Vignatelli L, Rinaldi R, Baldin E, Tinuper P, Michelucci R, Galeotti M, de Carolis P, D'Alessandro R. Impact of treatment on the short-term prognosis of status epilepticus in two population-based cohorts. J Neurol. 2008;255(2):197-204.
211. Silbergleit R, Lowenstein D, Durkalski V, Conwit R, Investigators N. Lessons from the rampart study - and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia. 2013;54(Suppl 6)74-7.
212. Silbergleit R, Lowenstein D, Durkalski V, Conwit R, Neurological Emergency Treatment Trials I. Rampart (rapid anticonvulsant medication prior to arrival trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(Suppl 8):45-7.
213. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59(2):205-10.
214. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251-6.
215. Kellinghaus C, Berning S, Stogbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129(5):294-9.
216. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, Jones E, Lowenstein D, Shinnar S, Silbergleit R, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89-92.
217. Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997;13(2):92-4.
218. Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, Ren Y, Fan CQ. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18(12):1391-6.
219. Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16(5):536-41.
220. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191-7.
221. McCormick EM, Lieh-Lai M, Knazik S, Nigro M. A prospective comparison of midazolam ans lorazepam in the initial treatment of status epilepticus in the pediatric patient. Epilepsia. 1999;40(s7):160.